CY1107276T1 - Μεταλλαγμενη ολοτοξινη χολερας ως ενα ανοσοενισχυτικο - Google Patents
Μεταλλαγμενη ολοτοξινη χολερας ως ενα ανοσοενισχυτικοInfo
- Publication number
- CY1107276T1 CY1107276T1 CY20081100125T CY081100125T CY1107276T1 CY 1107276 T1 CY1107276 T1 CY 1107276T1 CY 20081100125 T CY20081100125 T CY 20081100125T CY 081100125 T CY081100125 T CY 081100125T CY 1107276 T1 CY1107276 T1 CY 1107276T1
- Authority
- CY
- Cyprus
- Prior art keywords
- amino acid
- cholera
- allotoxin
- chlora
- immune
- Prior art date
Links
- 235000001014 amino acid Nutrition 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 4
- 206010008631 Cholera Diseases 0.000 abstract 3
- 239000002671 adjuvant Substances 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 239000003053 toxin Substances 0.000 abstract 2
- 231100000765 toxin Toxicity 0.000 abstract 2
- 108700012359 toxins Proteins 0.000 abstract 2
- 241000233866 Fungi Species 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- 244000052616 bacterial pathogen Species 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 229930186900 holotoxin Natural products 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Μια μεταλλαγμένη ολοτοξίνη χολέρας η οποία παρουσιάζει μια σημειακή μετάλλαξη στο αμινοξύ 29 της Α υπομονάδας, όπου το κατάλοιπο γλουταμινικού οξέος αντικαθίσταται από ένα αμινοξύ διαφορετικό του ασπαρτικού οξέος, είναι χρήσιμη ως ένα ανοσοενισχυτικό σε μια αντιγονική σύνθεση για ενίσχυση της άνοσης απόκρισης σε έναν σπονδυλωτό ξενιστή προς ένα επιλεγμένο αντιγόνο από ένα παθογόνο βακτήριο, ιό, μύκητα ή παράσιτο. Σε μια συγκεκριμένη υλοποίηση, το αμινοξύ 29 είναι ιστιδίνη. Η μεταλλαγμένη ολοτοξίνη χολέρας μπορεί να περιέχει μία επιπρόσθετη μετάλλαξη στην Α υπομονάδα σε μια θέση διαφορετική από αυτή του αμινοξέος 29. Η αντιγονική σύνθεση μπορεί να περιλαμβάνει ένα δεύτερο ανοσοενισχυτικό εκτός από την μεταλλαγμένη ολοτοξίνη χολέρας.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10243098P | 1998-09-30 | 1998-09-30 | |
EP99951639A EP1117435B1 (en) | 1998-09-30 | 1999-09-30 | Mutant cholera holotoxin as an adjuvant |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1107276T1 true CY1107276T1 (el) | 2012-11-21 |
Family
ID=22289805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081100125T CY1107276T1 (el) | 1998-09-30 | 2008-02-01 | Μεταλλαγμενη ολοτοξινη χολερας ως ενα ανοσοενισχυτικο |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1117435B1 (el) |
JP (1) | JP4673974B2 (el) |
KR (1) | KR100659803B1 (el) |
CN (1) | CN1197618C (el) |
AT (1) | ATE378066T1 (el) |
AU (1) | AU770333B2 (el) |
BR (1) | BR9914160A (el) |
CA (1) | CA2344740C (el) |
CY (1) | CY1107276T1 (el) |
DE (1) | DE69937571T2 (el) |
DK (1) | DK1117435T3 (el) |
ES (1) | ES2293735T3 (el) |
IL (2) | IL142231A0 (el) |
MX (1) | MXPA01003228A (el) |
PT (1) | PT1117435E (el) |
WO (1) | WO2000018434A1 (el) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9513371D0 (en) | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
WO1995009649A1 (en) | 1993-10-05 | 1995-04-13 | Medeva Holdings B.V. | Vaccine compositions |
GB9326174D0 (en) * | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
GB9622660D0 (en) | 1996-10-31 | 1997-01-08 | Biocine Spa | Immunogenic detoxified mutant toxin |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
US7115730B1 (en) | 1999-04-27 | 2006-10-03 | Chiron Srl | Immunogenic detoxified mutant E. coli LT-A-toxin |
KR100877019B1 (ko) | 2000-06-23 | 2009-01-07 | 와이어쓰 홀딩스 코포레이션 | 야생형 및 키메릭 인플루엔자 바이러스성입자(브이엘피)의 조립 |
JP4445200B2 (ja) | 2000-12-28 | 2010-04-07 | ワイス エルエルシー | $i(streptococcuspneumoniae)由来の組換え保護タンパク質 |
CN1636062A (zh) | 2001-04-16 | 2005-07-06 | 惠氏控股公司 | 编码多肽抗原的新肺炎链球菌可读框及其应用 |
IL159209A0 (en) | 2001-06-07 | 2004-06-01 | Wyeth Corp | Mutant forms of cholera holotoxin as an adjuvant |
DE60234695D1 (de) | 2001-06-07 | 2010-01-21 | Univ Colorado | Mutantenformen von cholera holotoxin als adjuvans |
DE60236596D1 (de) | 2001-07-27 | 2010-07-15 | Novartis Vaccines & Diagnostic | Antikörper gegen das meningokokken adhäsin app |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
GB0129007D0 (en) * | 2001-12-04 | 2002-01-23 | Chiron Spa | Adjuvanted antigenic meningococcal compositions |
WO2003078453A1 (en) | 2002-03-15 | 2003-09-25 | Wyeth Holdings Corporation | Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity |
US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
CA2519511A1 (en) * | 2003-03-17 | 2004-09-30 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
WO2004094596A2 (en) * | 2003-04-16 | 2004-11-04 | Wyeth Holdings Corporation | Novel immunogenic compositions for the prevention and treatment of meningococcal disease |
WO2005020902A2 (en) | 2003-08-21 | 2005-03-10 | Cytokine Pharmasciences, Inc. | Compositions and methods for treating and diagnosing irritable bowel syndrome |
TWI379839B (en) | 2003-12-17 | 2012-12-21 | Wyeth Llc | Aβ immunogenic peptide carrier conjugates and methods of producing same |
WO2005058940A2 (en) | 2003-12-17 | 2005-06-30 | Wyeth | Immunogenic peptide carrier conjugates and methods of producing same |
GB0410220D0 (en) | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
EP1749024A2 (en) | 2004-05-21 | 2007-02-07 | Wyeth a Corporation of the State of Delaware | Altered fibronectin-binding protein of staphylococcus aureus |
TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
EP1796719B1 (en) | 2004-10-06 | 2014-12-03 | MedImmune, LLC | Refrigerator-temperature stable influenza vaccine compositions |
EP2298341A3 (en) | 2004-10-21 | 2011-07-13 | Wyeth LLC | Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens |
US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
CN113198012A (zh) | 2005-04-08 | 2021-08-03 | 惠氏有限责任公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物 |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
DK2041270T3 (da) | 2006-07-13 | 2014-01-27 | Wyeth Llc | Fremstilling af glycoproteiner |
EP2395077A1 (en) | 2006-11-03 | 2011-12-14 | Wyeth LLC | Glycolysis-inhibiting substances in cell culture |
AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
WO2008109410A1 (en) | 2007-03-02 | 2008-09-12 | Wyeth | Use of copper and glutamate in cell culture for production of polypeptides |
US20120128684A1 (en) | 2008-08-25 | 2012-05-24 | Burnham Institute For Medical Research | Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use |
DK2356135T3 (en) | 2008-11-05 | 2017-12-04 | Wyeth Llc | IMMUNOGEN MULTICOMPONENT COMPOSITION FOR THE PREVENTION OF BETA-HAEMOLYTIC STRUCTURAL TOC (BHS) DISEASE |
CA2743306A1 (en) | 2008-11-12 | 2010-05-20 | Theraclone Sciences, Inc. | Human m2e peptide immunogens |
US9260691B2 (en) | 2010-05-19 | 2016-02-16 | Bioproperties Pty Ltd | Methods relating to an attenuated mycoplasma |
PT3170508T (pt) | 2010-06-04 | 2020-01-16 | Wyeth Llc | Formulações de vacinas |
PT3246044T (pt) | 2010-08-23 | 2021-02-15 | Wyeth Llc | Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis |
NZ607224A (en) | 2010-09-10 | 2014-11-28 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
ITMI20111182A1 (it) | 2011-06-28 | 2012-12-29 | Canio Buonavoglia | Vaccino per coronavirus canino |
RU2665841C2 (ru) | 2012-03-09 | 2018-09-04 | Пфайзер Инк. | Композиции neisseria meningitidis и способы их применения |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
KR102057217B1 (ko) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
EP2875041A2 (en) | 2012-07-19 | 2015-05-27 | Zoetis LLC | Bovine influenza c virus compositions |
WO2014018724A1 (en) | 2012-07-27 | 2014-01-30 | Zoetis Llc | Tick toxin compositions |
PL2885007T3 (pl) | 2012-08-16 | 2019-02-28 | Pfizer Inc. | Sposoby glikokoniugacji i kompozycje |
KR20140075201A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
KR20140075196A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
CA2903716C (en) | 2013-03-08 | 2019-04-09 | Pfizer Inc. | Immunogenic fusion polypeptides |
US20160008449A1 (en) | 2013-03-15 | 2016-01-14 | Zoetis Services Llc | CROSS-PROTECTION OF BOVINES AGAINST B. trehalosi INFECTION BY A MULTI-VALENT VACCINE |
KR20180099912A (ko) | 2013-09-08 | 2018-09-05 | 화이자 인코포레이티드 | 나이세리아 메닌지티디스 조성물 및 그의 방법 |
PT3096783T (pt) | 2014-01-21 | 2021-08-16 | Pfizer | Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos |
RU2688831C2 (ru) | 2014-01-21 | 2019-05-22 | Пфайзер Инк. | Капсульные полисахариды Streptococcus pneumoniae и их конъюгаты |
ES2701169T3 (es) | 2014-02-14 | 2019-02-21 | Pfizer | Conjugados glucoproteicos inmunogénicos |
CN107249626A (zh) | 2015-02-19 | 2017-10-13 | 辉瑞大药厂 | 脑膜炎奈瑟球菌组合物及其方法 |
ES2933623T3 (es) | 2015-08-14 | 2023-02-10 | Zoetis Services Llc | Composiciones de Mycoplasma Bovis |
WO2017123201A1 (en) | 2016-01-11 | 2017-07-20 | Zoetis Services Llc | Novel cross protective vaccine compositions for porcine epidemic diarrhea virus |
WO2017220753A1 (en) | 2016-06-22 | 2017-12-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
EP3269385A1 (en) | 2016-07-12 | 2018-01-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
AU2018215585B2 (en) | 2017-01-31 | 2022-03-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
GB201703529D0 (en) | 2017-03-06 | 2017-04-19 | Cambridge Entpr Ltd | Vaccine composition |
US10525119B2 (en) | 2017-03-31 | 2020-01-07 | Boston Medical Center Corporation | Methods and compositions using highly conserved pneumococcal surface proteins |
EP4327876A2 (en) | 2017-06-23 | 2024-02-28 | Affinivax, Inc. | Immunogenic compositions |
EP3574915A1 (en) | 2018-05-29 | 2019-12-04 | Neovacs | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
CN114728050A (zh) | 2019-07-31 | 2022-07-08 | 圣诺菲·帕斯图尔公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物及其使用方法 |
US20230233652A1 (en) | 2020-04-16 | 2023-07-27 | Par'immune Sas | 28 kda gst proteins from schistosoma for the treatment of vasculitis |
EP3900739A1 (en) | 2020-04-21 | 2021-10-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein |
JP2023542036A (ja) | 2020-09-17 | 2023-10-04 | ネオヴァクス | IgE介在性炎症性障害を治療するためのIgEフラグメントを含む免疫原性産物 |
WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL101715A (en) * | 1991-05-02 | 2005-06-19 | Amgen Inc | Recombinant dna-derived cholera toxin subunit analogs |
GB9513371D0 (en) * | 1995-06-30 | 1995-09-06 | Biocine Spa | Immunogenic detoxified mutant toxins |
AU6505796A (en) * | 1995-07-26 | 1997-02-26 | Maxim Pharmaceuticals | Mucosal delivery of polynucleotides |
GB9603314D0 (en) * | 1996-02-16 | 1996-04-17 | Biocine Spa | Immunogenic detoxified mutant toxins |
WO1998045324A1 (en) * | 1997-04-04 | 1998-10-15 | The Uab Research Foundation | Use of cholera toxin mutants as mucosal adjuvants |
-
1999
- 1999-09-30 PT PT99951639T patent/PT1117435E/pt unknown
- 1999-09-30 EP EP99951639A patent/EP1117435B1/en not_active Expired - Lifetime
- 1999-09-30 KR KR1020017003968A patent/KR100659803B1/ko not_active IP Right Cessation
- 1999-09-30 DK DK99951639T patent/DK1117435T3/da active
- 1999-09-30 AT AT99951639T patent/ATE378066T1/de not_active IP Right Cessation
- 1999-09-30 BR BR9914160-4A patent/BR9914160A/pt not_active Application Discontinuation
- 1999-09-30 CA CA2344740A patent/CA2344740C/en not_active Expired - Fee Related
- 1999-09-30 CN CNB998115576A patent/CN1197618C/zh not_active Expired - Fee Related
- 1999-09-30 WO PCT/US1999/022520 patent/WO2000018434A1/en active IP Right Grant
- 1999-09-30 ES ES99951639T patent/ES2293735T3/es not_active Expired - Lifetime
- 1999-09-30 AU AU64039/99A patent/AU770333B2/en not_active Ceased
- 1999-09-30 DE DE69937571T patent/DE69937571T2/de not_active Expired - Lifetime
- 1999-09-30 IL IL14223199A patent/IL142231A0/xx unknown
- 1999-09-30 JP JP2000571951A patent/JP4673974B2/ja not_active Expired - Fee Related
- 1999-09-30 MX MXPA01003228A patent/MXPA01003228A/es not_active IP Right Cessation
-
2001
- 2001-03-25 IL IL142231A patent/IL142231A/en not_active IP Right Cessation
-
2008
- 2008-02-01 CY CY20081100125T patent/CY1107276T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CN1197618C (zh) | 2005-04-20 |
MXPA01003228A (es) | 2003-06-24 |
KR20010085859A (ko) | 2001-09-07 |
JP4673974B2 (ja) | 2011-04-20 |
DE69937571T2 (de) | 2008-09-04 |
ATE378066T1 (de) | 2007-11-15 |
ES2293735T3 (es) | 2008-03-16 |
DK1117435T3 (da) | 2008-03-17 |
EP1117435A1 (en) | 2001-07-25 |
BR9914160A (pt) | 2001-06-26 |
CA2344740A1 (en) | 2000-04-06 |
CA2344740C (en) | 2011-11-22 |
EP1117435B1 (en) | 2007-11-14 |
PT1117435E (pt) | 2008-02-21 |
JP2002525093A (ja) | 2002-08-13 |
WO2000018434A1 (en) | 2000-04-06 |
IL142231A0 (en) | 2002-03-10 |
KR100659803B1 (ko) | 2006-12-19 |
IL142231A (en) | 2010-05-31 |
AU770333B2 (en) | 2004-02-19 |
AU6403999A (en) | 2000-04-17 |
CN1320043A (zh) | 2001-10-31 |
DE69937571D1 (de) | 2007-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107276T1 (el) | Μεταλλαγμενη ολοτοξινη χολερας ως ενα ανοσοενισχυτικο | |
BR9906927A (pt) | Proteìnas de neisseria meningitidis | |
ATE451386T1 (de) | Mutantenformen von cholera holotoxin als adjuvans | |
BR0210216A (pt) | Holotoxina do cólera imunogênica, mutante (ct-crm), composição imunogênica, métodos para aumentar a resposta imune de um hospedeiro vertebrado a um antìgeno, e para produzir uma holotoxina do cólera imunogênica, mutante, sequência ou molécula de ácido nucleico isolado e purificado, célula hospedeira, e, uso de uma holotoxina do cólera mutante | |
DK1545597T3 (da) | Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons | |
DE122010000042I1 (de) | Solubilisierung von capsulären Polysacchariden | |
BR9813930A (pt) | antìgeno neisserial | |
BR9910089A (pt) | Composições e antìgenos de neisseria meningitidis | |
DE69733020D1 (de) | Immunostimulierende oligonucleotidekonjugate | |
DK1113816T3 (da) | Influenzavirus-vaccinesammensætning | |
CY1108526T1 (el) | Εμβολια εναντι καρκινων | |
ATE392216T1 (de) | Mycobakterieller impfstoff | |
DE60011560D1 (de) | Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert | |
DK0757556T3 (da) | Borrelia Burgdorferi-bakterin | |
HUP0104552A2 (hu) | Orális vakcina hasmenés ellen | |
FI971402A0 (fi) | Menetelmä voimistettujen antigeenisten Helico-bacter-lajien ja niitä sisältävien rokotteiden valmistamiseksi | |
DK1350796T3 (da) | Attenuerede gramnegative bakterier | |
ATE195427T1 (de) | Pertussistoxin enthaltender influenzaimpfstoff |